IL13 and Alzheimer disease: Trials have shown that new selective JAK inhibitors also suppress key itch-related cytokine signaling pathways needed for the Th1, Th2, and Th22 responses (including IL-4, IL-13, TSLP, IL-31, and IL-22) and are likely suitable treatment options for AD with broader immune activation46–48.